title: Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation.
abstract: This study investigated the use of low dose methotrexate (MTX) (5 mg/m2/infusion) for the treatment of graft-versus-host disease (GVHD), after failure of corticosteroids. Twelve patients had refractory acute GVHD, while eight received MTX for severe chronic GVHD and/or the side effects of corticosteroids. Thirteen patients responded to MTX with six complete remissions and little toxicity, suggesting that low dose MTX is beneficial in refractory GVHD and deserves further investigations.
authors.forename: Hugues
authors.initials: H
authors.lastname: de Lavallade
authors.forename: Mohamad
authors.initials: M
authors.lastname: Mohty
authors.forename: Catherine
authors.initials: C
authors.lastname: Faucher
authors.forename: Sabine
authors.initials: S
authors.lastname: Fürst
authors.forename: Jean
authors.initials: J
authors.lastname: El-Cheikh
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
mesh_terms: D000328:Adult; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D016879:Salvage Therapy / Q000379:methods*; D033581:Stem Cell Transplantation / Q000379:methods; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous
chemical_list: D008727:Methotrexate